{"nctId":"NCT00856583","briefTitle":"Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use","startDateStruct":{"date":"2002-07"},"conditions":["Schizophrenia"],"count":9809,"armGroups":[{"label":"Sertindole","type":"EXPERIMENTAL","interventionNames":["Drug: Sertindole"]},{"label":"Risperidone","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Risperidone"]}],"interventions":[{"name":"Sertindole","otherNames":["Serdolect"]},{"name":"Risperidone","otherNames":["Risperdal"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* The patient has signed the Informed Consent Form or, if he/she is not able to sign it (according to the ICH GCP guidelines and the Declaration of Helsinki), the patient's legal representative has signed the Informed Consent Form\n* The patient has been diagnosed with schizophrenia\n* Based on the patient's clinical status, new or change of antipsychotic treatment is indicated\n* The patient is at least 18 years of age\n* The patient meets the criteria set out in the national SPCs for sertindole and risperidone. For those countries in which sertindole was not marketed, the EU SPC applied\n\nExclusion Criteria:\n\n* The last treatment taken by the patient was sertindole or risperidone\n* The patient has never previously received any antipsychotic drug therapy\n* The patient has contraindications to treatment with either sertindole or risperidone\n* In addition to sertindole/risperidone, treatment with another antipsychotic is indicated\n* The patient is homeless\n* The patient has previously been included in one of the two H. Lundbeck A/S post-marketing studies, 99823 or 99824\n* The patient is, in the opinion of the investigator, unlikely to comply with the study protocol or unsuitable for any other reason","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With All-cause Mortality","description":"The analysis was based on all deaths from the Whole Randomised Treatment (WRT)+30 days period and the Only Randomised Treatment (ORT) period, respectively","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"44","spread":null}]}]}]},{"type":"SECONDARY","title":"Cause-specific Mortality: Number of Participants With Cardiac Deaths - ISC","description":"The analysis was based on all deaths from the WRT+30 days period using the classification performed by the ISC.\n\nThe ISC reviewed and classified those adverse events which resulted in death or hospitalisation or were possible suicide attempts and this review was blinded to exposure. The definition of cardiac death was intentionally wide; sudden or unexplained deaths were assumed to be cardiac if there was no non-cardiac explanation. To ensure consistent evaluation and classification, the ISC decided a priori to classify all instances of self harm as possible suicide.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]}]},{"type":"PRIMARY","title":"Second Primary Outcome: Number of Participants With Cardiac Events, Including Arrhythmias, Requiring Hospitalisation","description":"Second primary endpoint: a serious adverse event where the patient was hospitalised and for which the Independent Safety Committee (ISC) classified the event as a cardiac event with documented arrhythmia. The analysis of this outcome was not performed due to low number of events. The presented analysis is a replacement analysis using all cardiac events, including arrhythmias, that required hospitalisation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Cause-specific Mortality: Number of Participants With Completed Suicides - ISC","description":"The analysis was based on all deaths from the WRT+30 days period using the classification performed by the ISC.\n\nThe ISC reviewed and classified those adverse events which resulted in death or hospitalisation or were possible suicide attempts and this review was blinded to exposure. The definition of cardiac death was intentionally wide; sudden or unexplained deaths were assumed to be cardiac if there was no non-cardiac explanation. To ensure consistent evaluation and classification, the ISC decided a priori to classify all instances of self harm as possible suicide.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]}]},{"type":"SECONDARY","title":"Cause-specific Mortality: Number of Participants With Other Than Cardiac Deaths and Completed Suicides - ISC","description":"The analysis was based on all deaths from the WRT+30 days period using the classification performed by the ISC.\n\nThe ISC reviewed and classified those adverse events which resulted in death or hospitalisation or were possible suicide attempts and this review was blinded to exposure. The definition of cardiac death was intentionally wide; sudden or unexplained deaths were assumed to be cardiac if there was no non-cardiac explanation. To ensure consistent evaluation and classification, the ISC decided a priori to classify all instances of self harm as possible suicide.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]}]},{"type":"SECONDARY","title":"Cause-specific Mortality: Number of Participants With Cardiac Deaths - MedDRA","description":"The analysis was based on all deaths from the WRT+30 days period using the classification based upon the Medical Dictionary for Regulatory Activities (MedDRA) terminology, that is, as reported by the investigator","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Cause-specific Mortality: Number of Participants With Completed Suicides - MedDRA","description":"The analysis was based on all deaths from the WRT+30 days period using the classification based upon MedDRA terminology, that is, as reported by the investigator","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]}]},{"type":"SECONDARY","title":"Cause-specific Mortality: Number of Participants With Other Than Cardiac Deaths and Completed Suicides - MedDRA","description":"The analysis was based on all deaths from the WRT+30 days period using the classification based upon MedDRA terminology, that is, as reported by the investigator","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Suicide Attempts (Fatal and Non-fatal) - ISC","description":"The analysis was based on all suicides and suicide attempts from the WRT+30 days period using the classification performed by the ISC.\n\nThe ISC reviewed and classified those adverse events which resulted in death or hospitalisation or were possible suicide attempts and this review was blinded to exposure. The definition of cardiac death was intentionally wide; sudden or unexplained deaths were assumed to be cardiac if there was no non-cardiac explanation. To ensure consistent evaluation and classification, the ISC decided a priori to classify all instances of self harm as possible suicide.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null},{"groupId":"OG001","value":"76","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Suicide Attempts (Fatal and Non-fatal) - MedDRA","description":"The analysis was based on all suicides and suicide attempts from the WRT+30 days period using the classification based upon MedDRA terminology, that is, as reported by the investigator","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"65","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Hospitalisations, Excluding Hospitalisations Related to the Primary Psychiatric Disease","description":"The analysis was based on time from start of study drug to first hospitalisation during the WRT+30 days period","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"174","spread":null},{"groupId":"OG001","value":"149","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Discontinuation of Treatment for Any Reason Other Than Study Closure","description":"The analysis was based on time from start of study drug until stop of study drug for any reason other than sponsor closure of the study","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3136","spread":"430 PET?"},{"groupId":"OG001","value":"2597","spread":"433"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":266,"n":4905},"commonTop":["Electrocardiogram QT prolonged"]}}}